NASDAQ · XBIO
Healthcare · Biotechnology
$2.19
Down-$2.08 (-48.71%)
Updated Sep 17, 2026, 7:33 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
XBIO closed at $2.19 after 20 trading sessions, down 34.82% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $2.75 | $2.7888 | $1.87 | $2.19 | 1.51M |
| Sep 15, 2026 | $4.33 | $4.33 | $4.0882 | $4.27 | 5.88K |
| Sep 14, 2026 | $4.00 | $4.33 | $3.8522 | $4.33 | 66.84K |
| Sep 11, 2026 | $4.07 | $4.11 | $3.8367 | $3.90 | 37.65K |
| Sep 10, 2026 | $4.15 | $4.20 | $4.06 | $4.07 | 17.42K |
| Sep 9, 2026 | $4.26 | $4.30 | $4.11 | $4.215 | 26.82K |
| Sep 8, 2026 | $4.67 | $4.76 | $4.00 | $4.28 | 86.15K |
| Sep 4, 2026 | $4.73 | $4.9039 | $4.41 | $4.67 | 79.17K |
| Sep 3, 2026 | $4.27 | $4.9392 | $4.27 | $4.63 | 139.6K |
| Sep 2, 2026 | $4.23 | $4.4317 | $4.08 | $4.25 | 24.9K |
| Sep 1, 2026 | $4.20 | $4.25 | $4.00 | $4.23 | 26.58K |
| Aug 31, 2026 | $3.99 | $4.2999 | $3.9535 | $4.19 | 30.3K |
| Aug 28, 2026 | $4.01 | $4.06 | $3.90 | $3.98 | 19.59K |
| Aug 27, 2026 | $3.91 | $4.00 | $3.86 | $3.97 | 23.93K |
| Aug 26, 2026 | $3.78 | $3.88 | $3.70 | $3.86 | 22.42K |
| Aug 25, 2026 | $3.81 | $3.82 | $3.58 | $3.82 | 27.36K |
| Aug 24, 2026 | $3.74 | $4.05 | $3.5301 | $3.81 | 102.79K |
| Aug 21, 2026 | $3.36 | $3.73 | $3.18 | $3.59 | 84.26K |
| Aug 20, 2026 | $3.41 | $3.4103 | $3.28 | $3.39 | 9.27K |
| Aug 19, 2026 | $3.24 | $3.36 | $3.18 | $3.36 | 14.55K |
The latest Smart Investors Daily articles mentioning XBIO.
XBIO research
Company profile and research snapshot.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 9, 2025 | HC Wainwright & Co. | Neutral | — |
| Mar 20, 2025 | HC Wainwright & Co. | Neutral | — |
| Dec 5, 2024 | HC Wainwright & Co. | Neutral | — |
| Nov 22, 2024 | HC Wainwright & Co. | Neutral | — |
| Aug 20, 2024 | HC Wainwright & Co. | Neutral | — |
No generated briefing is available yet.
Benzinga · Aug 7, 2026
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.41) per share. This is a 8.89 percent increase over losses of $(0.45) per share from the same period last year. The company reported $660.601 thousand
Benzinga · Mar 13, 2026
Xenetic Biosciences (NASDAQ:XBIO) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.52) by 57.69 percent. This is a 67.65 percent increase over losses of $(0.68) per share
accessnewswire.com · Dec 11, 2025
Adjourns 2025 Annual Meeting of Stockholders Urges Stockholders Who Have Not Voted To Get Votes In FRAMINGHAM, MA / ACCESS Newswire / December 11, 2025 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today announced that its 2025 Annual Meeting of Stockholders (the "Annual Meeting") was convened and adjourned without any business conducted due to lack of the required quorum. A quorum is necessary to hold the Annual Meeting.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning XBIO.
